Journal profile · DERMATOLOGY
Psoriasis-Targets and Therapy
ISSN 2230-326X · Dove Medical Press · United Kingdom
Psoriasis-Targets and Therapy: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.9 (journal website); JCR Q1 (journal website); fully open access; APC about USD 3,565; median 98 days to acceptance (83 articles, last 24 months); acceptance rate 21% (journal website); 48 articles in 2025; indexed in ESCI.
Scope
Aims, scope and focus
Psoriasis-Targets and Therapy is published by Dove Medical Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Psoriasis: Treatment and Pathogenesis, Spondyloarthritis Studies and Treatments and Dermatology and Skin Diseases, together about 68.4% of its articles. Its main subfields are Dermatology. (generated from OpenAlex topic counts and CAS ranking data)
Editor-in-Chief: Dr Tina Bhutani Psoriasis: Targets and Therapy is an international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life. Psoriasis: Targets and Therapy will no longer consider meta-analyses for publication. Specific topics covered in the journal include: Epidemiology, etiology and prognosis Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of traditional and biologic agents, including combination therapies Phototherapy and alternative therapies Patient adherence, quality of life, satisfaction Health economic evaluations Updated 6 August 2025
From the journal's Aims & Scope
Research area (LetPub): DERMATOLOGY
Editor-in-chief Tina BhutaniPublisher website
Editorial board by country: none in mainland China; most named Italy 10, United States 6, Japan 2, France 2, Canada 2 (31 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Psoriasis: Treatment and PathogenesisImmunology and Microbiology36.9%
- Spondyloarthritis Studies and TreatmentsMedicine16.3%
- Dermatology and Skin DiseasesMedicine15.2%
- Rheumatoid Arthritis Research and TherapiesMedicine4.2%
- Autoimmune Bullous Skin DiseasesMedicine4%
- Skin Diseases and DiabetesMedicine2.4%
- Biological Research and Disease StudiesBiochemistry, Genetics and Molecular Biology2%
- Pharmaceutical studies and practicesMedicine1.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Dermatology | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Dermatology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
JCR / CiteScore quartiles on the journal's website
- JCR Q1 · best quartile · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
ESCIDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCEmbasePublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 4.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.9Publisher website ·
- h-index
- 35OpenAlex ·
- i10-index
- 88OpenAlex ·
- 2-year mean citedness
- 2.73OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 48LetPub ·
- Articles per year (publisher)
- 50Publisher website ·
- Downloads per year (publisher)
- 34,130Publisher website ·
Articles by year OpenAlex count · 232 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 27 | 27 | 3 |
| 2025 | 48 | 48 | 142 |
| 2024 | 23 | 23 | 123 |
| 2023 | 7 | 7 | 110 |
| 2022 | 22 | 22 | 628 |
| 2021 | 14 | 14 | 354 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
98 daysMedian, submission to acceptance · P25–P75 79 days – 118 days
- Acceptance to online
- median 17 days (83 articles)
- Submission to online
- median 117 days
- Sample
- 83 articles with submission and acceptance dates (86 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 16 weeksLetPub ·
- Acceptance rate (publisher)
- 21%Publisher website ·
- Desk decision
- 54 daysPublisher website ·
- Submission to publication (journal-reported)
- about 16 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,565 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,320 | — | — | |
| LetPub | USD 2,990 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted3
- case reportAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
- editorialEditorialLength not stated
- reviewAuthors may use these detailed descriptions of different paper types accepted by Dove Medical Press (case reports, reviews, etc) to decide how to label their pa…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review
- Publication ethics
Member of and subscribes to the principles of the Committee on Publication Ethics (COPE) Model summary
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE).
Source ↗Publisher website ·- Peer review
Meta-analyses no longer considered for publication. Model summary
Psoriasis: Targets and Therapy will no longer consider meta-analyses for publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Dove Medical Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2230-326X
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Psoriasis-Targets and Therapy
What CAS zone is Psoriasis-Targets and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Psoriasis-Targets and Therapy is in Zone 3 of Medicine, and in Zone 2 of the minor category Dermatology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Psoriasis-Targets and Therapy?
The journal's website gives an impact factor of 4.9 (2025); this is the journal's own figure, as LetPub lists none for it; h-index 35.
How long does peer review take at Psoriasis-Targets and Therapy?
Based on the dates recorded on 83 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 98 days (interquartile range 79–118 days); authors report an average review time of about 16 weeks; the journal's website gives an acceptance rate of 21%. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Psoriasis-Targets and Therapy in?
The journal's website gives JCR Q1 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Where are the editorial board members of Psoriasis-Targets and Therapy based?
Of the 31 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (10), United States (6) and Japan (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Psoriasis-Targets and Therapy?
According to LetPub and DOAJ records, Psoriasis-Targets and Therapy is indexed in ESCI and DOAJ. The journal's website also lists PMC and Embase; that list has not been checked against each database.
Is Psoriasis-Targets and Therapy open access, and what is the APC?
Psoriasis-Targets and Therapy is a fully open-access journal. APC about USD 3,565.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .